INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone
December 18, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology
December 17, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
December 04, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and...
Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting
November 20, 2018 07:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory...
INSYS Therapeutics Reports Third Quarter 2018 Results
November 05, 2018 16:16 ET
|
INSYS Therapeutics, Inc.
Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS...
INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets
November 05, 2018 16:15 ET
|
INSYS Therapeutics, Inc.
Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development,...
INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose
November 01, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Nov. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), today announced that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray...
INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5
October 22, 2018 17:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies
October 12, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...